LABIANA HEALTH S.A.EO-10 (8RK) - Total Assets
Based on the latest financial reports, LABIANA HEALTH S.A.EO-10 (8RK) holds total assets worth €54.38 Million EUR (≈ $63.57 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does LABIANA HEALTH S.A.EO-10 reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
LABIANA HEALTH S.A.EO-10 - Total Assets Trend (2021–2024)
This chart illustrates how LABIANA HEALTH S.A.EO-10's total assets have evolved over time, based on quarterly financial data. Check 8RK cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
LABIANA HEALTH S.A.EO-10 - Asset Composition Analysis
Current Asset Composition (December 2024)
LABIANA HEALTH S.A.EO-10's total assets of €54.38 Million consist of 55.2% current assets and 44.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.0% |
| Accounts Receivable | €9.42 Million | 18.1% |
| Inventory | €9.98 Million | 19.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.03 Million | 11.6% |
| Goodwill | €-0.01 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how LABIANA HEALTH S.A.EO-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LABIANA HEALTH S.A.EO-10 (8RK) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LABIANA HEALTH S.A.EO-10's current assets represent 55.2% of total assets in 2024, an increase from 43.0% in 2021.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2024, up from 4.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 17.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
LABIANA HEALTH S.A.EO-10 Competitors by Total Assets
Key competitors of LABIANA HEALTH S.A.EO-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
LABIANA HEALTH S.A.EO-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.32 | 1.32 |
| Quick Ratio | 0.86 | 0.80 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €9.19 Million | €6.89 Million | €6.89 Million |
LABIANA HEALTH S.A.EO-10 - Advanced Valuation Insights
This section examines the relationship between LABIANA HEALTH S.A.EO-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.89 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | -12.0% |
| Total Assets | €52.00 Million |
| Market Capitalization | $62.40 Million USD |
Valuation Analysis
Above Book Valuation: The market values LABIANA HEALTH S.A.EO-10's assets above their book value (1.20x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: LABIANA HEALTH S.A.EO-10's assets decreased by 12.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LABIANA HEALTH S.A.EO-10 (2021–2024)
The table below shows the annual total assets of LABIANA HEALTH S.A.EO-10 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €52.00 Million ≈ $60.80 Million |
-12.05% |
| 2023-12-31 | €59.12 Million ≈ $69.12 Million |
-2.72% |
| 2022-12-31 | €60.78 Million ≈ $71.06 Million |
-11.10% |
| 2021-12-31 | €68.37 Million ≈ $79.93 Million |
-- |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more